$CBIO potential to make a large move 🔥$CBIO looks like it has potential to make a large move soon, Also it's #4 in list of top Fintel Gamma Squeeze list📈
CBIO
CBIO - DAILY CHART Hi, today we are going to talk about Catalyst Biosciences and its current landscape.
Catalyst Biosciences is poised to receive increasing attention from the market as relevant events are taking place. The clinical-stage biopharmaceutical company has been soaring over the announcement that the company entered into a global science collaboration agreement with Biogen for the development and commercialization of pegylated CB-2782. Catalyst Biosciences it's going to receive $15 million upfront payment and is poised to receive up to $340 million down the road, also royalties of the sales. A context that sets Catalyst Biosciences to a skyrocket movement as is expected that its earnings are going to overcome expectations in the next quarters easily than ever.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
NeuroMetrix, Inc, Low Float, Lands Deal With GlaxoSmithKlineNew and innovative product. Quell's proven technology is 5x more powerful on average than other over-the-counter pain relief devices. It is discreet and completely wearable to enable pain relief when your patients need it.
Increased quarterly earnings growth.
Low floater
Resistance at at 3.00 range due to the preferred shares being exercisible at 2.83
Target is 2.50. Nice day trade potential. They just had the biggest trading volume in a very long time, by a long shot.
CBIO - Fallen angel formation Day trade from $4.70 to $4.94CBIO seems forming a very nice fallen angel formation. It has history of sharp breakout, and at this time it seems getting ready for another breakout. We are looking for a quick day trade if it breaks above $4.70
* Trade Criteria *
Date First Found- June 29, 2017
Pattern/Why- Fallen angel formation
Entry Target Criteria- Break of $4.70
Exit Target Criteria- $4.94
Stop Loss Criteria- $4.60
Please check back for Trade updates. (Note: Trade update is little delayed here.)
Potential Long position CBIOU.S. Government Required Disclaimer - Commodity Futures Trading Commission Futures, Stocks and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures, stocks or options on the same. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.
CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.
NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL, OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE DISCUSSED WITHIN THIS SITE, SUPPORT AND TEXTS. OUR COURSE(S), PRODUCTS AND SERVICES SHOULD BE USED AS LEARNING AIDS ONLY AND SHOULD NOT BE USED TO INVEST REAL MONEY. IF YOU DECIDE TO INVEST REAL MONEY, ALL TRADING DECISIONS SHOULD BE YOUR OWN.
Newest Alert is $CBIO$CBIO Recent Highlights and Upcoming Milestones
Recent Highlights:
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis of $0.2 million.
Cash, cash equivalents and short-term investments as of March 31, 2017 were $14.5 million
The Company believes that its existing capital resources will be sufficient to meet its projected operating requirements for at least the next 12 months.
Raised $20.7 million through an underwritten public equity offering that included the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants on April 12, 2017
Achieved key milestones with CB 2679d/ISU304, the Company’s next-generation coagulation Factor IX, as follows:
Investigational New Drug (IND) application approved by the Korean Ministry of Food and Drug Safety (MFDS)
Completion of IND-enabling toxicology studies triggered a milestone payment from Catalyst’s collaboration partner, ISU Abxis
Advanced the development of marzeptacog alfa (activated), the Company’s next-generation Factor VIIa, including the following accomplishments:
Received notice from the European Patent Office that the opposition period, for a patent granted to Catalyst, has expired and no opposition has been filed
Selected a global contract research organization, INC Research, to conduct the Phase 2/3 efficacy clinical trial of marzeptacog alfa (activated) in individuals with hemophilia A or B with an inhibitor
Anticipated Milestones
CB 2679d/ISU304: Initiate a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B in the second quarter of 2017; the trial will be conducted by Catalyst’s collaborator, ISU Abxis (KOSDAQ: 086890) in South Korea
Marzeptacog alfa (activated): Initiate the Phase 2 part of a Phase 2/3 efficacy clinical trial in individuals with hemophilia A or B with an inhibitor in the fourth quarter of 2017
